Medical Science 2023 Paper I 50 marks Discuss

Q7

(a) Classify the various types of poisons. Enumerate the features of Plumbism. Discuss the tests which will show/establish the onset of early stages of Pb poisoning. 5+5+5=15 (b) (i) A 29-year-old female presented with fever, multiple episodes of epistaxis and gum bleeding since one month. On examination, her temperature was 37·6°C. Skin showed multiple bruises. CBC showed Hb – 8·2 g/dL, WBC count – 60,000/µL. Peripheral smear showed 75% plasts. They had fine cytoplasmic azurophilic granules and Auer rods. (I) What is the most likely diagnosis ? (II) Enumerate the cytochemical stains useful in this disease. (III) Write two cytogenetic abnormalities with favourable prognosis. (IV) Mention two cytogenetic abnormalities with unfavourable prognosis. 2+4+2+2=10 (ii) Describe the aetiopathogenesis and microscopic findings in affected heart of rheumatic heart disease. 5+5=10 (c) (i) Discuss the management of complicated *Plasmodium falciparum* malaria. 10 (ii) Discuss the therapeutic indications and adverse effects of Insulin. 5

हिंदी में प्रश्न पढ़ें

(a) विभिन्न प्रकार के विष वर्गीकृत कीजिए । सीसात्वय की विशेषताओं को गिनाइए । Pb विषाक्तता की आरंभिक अवस्था के आगमन को स्थापित करने वाली जाँचों की व्याख्या कीजिए । 5+5+5=15 (b) (i) एक 29-वर्षीय महिला को विगत एक माह से बुखार है, नासारक्तस्रावण की घटनाएँ हो रही हैं और मसूड़ों से खून जाने के प्रसंग हो रहे हैं । जाँच करने पर उसका शारीरिक तापमान 37·6°C है । त्वचा पर बहुत से नील हैं । CBC जाँच करने पर हीमोग्लोबिन 8·2 g/dL है, WBC गणना 60,000/μL है । पेरिफरल स्मीयर देखने पर उसमें 75% प्रसू हैं, जिनके कोशिकाद्रव्य में सूक्ष्म अणुरोफिलिक कणिकाएँ हैं तथा ऑर (Auer) शलाकाएँ हैं । (I) सर्वाधिक संभावित निदान क्या है ? (II) इस रोग में उपयोगी साइटोकैमिकल अभिरंजकों के नाम गिनाइए । (III) दो ऐसी कोशिकानुवंशिक अपसामान्यताएँ लिखिए जो अनुकूल पूर्वानुमान की घोतक हैं । (IV) दो ऐसी कोशिकानुवंशिक अपसामान्यताएँ लिखिए जो प्रतिकूल पूर्वानुमान की घोतक हैं । 2+4+2+2=10 (ii) रूमेटी हृदय रोग की हेतुकीविकृतिजन तथा इस रोग से प्रभावित हृदय में मिलने वाली सूक्ष्मदर्शिकी विशेषताओं का वर्णन कीजिए । 5+5=10 (c) (i) जटिल प्लाज़्मोडियम फैल्सीपेरम मलेरिया के प्रबंधन की व्याख्या कीजिए । 10 (ii) इंसुलिन के चिकित्सार्थ संकेतों तथा प्रतिकूल प्रभावों की व्याख्या कीजिए । 5

Directive word: Discuss

This question asks you to discuss. The directive word signals the depth of analysis expected, the structure of your answer, and the weight of evidence you must bring.

See our UPSC directive words guide for a full breakdown of how to respond to each command word.

How this answer will be evaluated

Approach

Begin with a brief introduction acknowledging the multi-system nature of the question spanning toxicology, hematology, cardiology, infectious disease and pharmacology. For part (a), allocate ~25% time covering poison classification with examples (corrosive, metallic, gaseous, organic), detailed Plumbism features (Burtonian line, wrist drop, anemia), and early diagnostic tests (urinary ALA, coproporphyrin, blood zinc protoporphyrin). For part (b)(i), spend ~20% on AML-M3 diagnosis, cytochemical stains (MPO, Sudan Black, NSE), and cytogenetics (t(15;17) favorable; -7, -5 unfavorable). For part (b)(ii), allocate ~20% describing rheumatic fever pathogenesis (molecular mimicry, Aschoff body) with microscopic findings. For part (c)(i), devote ~25% to complicated falciparum malaria management (IV artesunate, exchange transfusion criteria). For part (c)(ii), spend ~10% on insulin indications (DKA, HHS, Type 1 DM) and adverse effects (hypoglycemia, lipodystrophy). Conclude with integrative remarks on preventive aspects where relevant.

Key points expected

  • Part (a): Classification of poisons by chemical nature (corrosive, metallic, gaseous, organic, vegetable, animal, mechanical) with Indian examples; Plumbism features including Burtonian line, lead colic, wrist drop, basophilic stippling, anemia; early diagnostic tests: urinary ALA, coproporphyrin, blood ZPP, serum lead levels
  • Part (b)(i): Diagnosis of Acute Promyelocytic Leukemia (AML-M3) based on Auer rods and clinical presentation; cytochemical stains: MPO positive, Sudan Black positive, NSE negative; favorable cytogenetics: t(15;17)(q24;q21) PML-RARA, t(8;21); unfavorable: monosomy 7, monosomy 5, 11q23 abnormalities
  • Part (b)(ii): Rheumatic heart disease pathogenesis: Group A streptococcal pharyngitis, molecular mimicry, autoimmune reaction; microscopic findings: Aschoff bodies with Anitschkow cells, fibrinoid necrosis, perivascular granulomatous inflammation
  • Part (c)(i): Complicated P. falciparum malaria management: IV artesunate as first-line, quinine alternative, exchange transfusion criteria (parasitemia >10% or >5% with complications), supportive care, prevention of blackwater fever
  • Part (c)(ii): Insulin therapeutic indications: Type 1 DM, DKA, HHS, gestational diabetes, perioperative hyperglycemia; adverse effects: hypoglycemia, weight gain, lipodystrophy, allergic reactions, insulin resistance

Evaluation rubric

DimensionWeightMax marksExcellentAveragePoor
Concept correctness25%12.5Demonstrates precise knowledge across all sub-parts: accurate poison classification with examples, correct Plumbism pathophysiology, accurate AML-M3 diagnosis with proper cytogenetic associations, correct rheumatic fever autoimmune mechanism, accurate complicated malaria WHO criteria and insulin pharmacologyShows generally correct concepts with minor errors in classification details, some confusion between cytogenetic prognostic groups, or incomplete pathogenesis explanationMajor conceptual errors such as wrong poison categories, incorrect diagnosis (confusing AML with ALL), wrong cytogenetic associations, or fundamental misunderstanding of insulin mechanisms
Clinical correlation20%10Effectively links laboratory findings to clinical presentation in all cases: connects lead exposure history to diagnostic tests, correlates Auer rods with DIC risk in APL, relates rheumatic valvular lesions to clinical murmurs, and ties parasitemia levels to cerebral malaria complicationsMakes some clinical connections but misses critical links such as DIC in APL, or fails to mention specific clinical scenarios for insulin usePurely theoretical answer with no clinical application; fails to mention presenting features, complications, or real-world diagnostic approach
Diagram / pathway15%7.5Includes labeled diagram of Aschoff body structure, heme synthesis pathway showing lead inhibition points, or flowchart for complicated malaria management; diagrams enhance answer clarity and demonstrate visual understandingMentions need for diagrams but provides poorly labeled or incomplete sketches; or describes pathways verbally without visual representationNo diagrams despite clear opportunities (Aschoff body, heme synthesis, malaria treatment algorithm); purely text-based answer where visual aid would strengthen response
Differential / staging20%10Provides clear differentials: for poisoning (arsenic, thallium vs lead), for leukemia (AML subtypes M0-M7, vs ALL), for fever with bleeding (ITP, aplastic anemia, dengue); mentions staging systems where relevant (Rheumatic fever Jones criteria, malaria severity WHO classification)Lists some differentials but incomplete; mentions staging without detail or misses key differentials like dengue in bleeding patientNo differentials provided; fails to distinguish between AML subtypes or confuses metallic poisonings; no mention of disease severity classification
Management / public-health angle20%10Comprehensive management including: chelation therapy for lead (EDTA, BAL, succimer), ATRA for APL, penicillin prophylaxis for rheumatic fever, artesunate-based combination therapy for malaria; includes public health measures: lead paint regulation, malaria vector control, National Vector Borne Disease Control ProgrammeCovers basic management but misses specific drugs (e.g., omits ATRA for APL), or provides generic advice without specific protocols; limited public health discussionIncomplete or incorrect management (oral antimalarials for complicated malaria, wrong chelating agents); no public health perspective; omits preventive strategies entirely

Practice this exact question

Write your answer, then get a detailed evaluation from our AI trained on UPSC's answer-writing standards. Free first evaluation — no signup needed to start.

Evaluate my answer →

More from Medical Science 2023 Paper I